NCT03033446View on ClinicalTrials.gov

Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

December 31, 2025

Conditions
HepatoCellular Carcinoma
Interventions
RADIATION

Y-90 Radioembolization

Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan

DRUG

Nivolumab

21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks

Trial Locations (1)

169610

National Cancer Centre - Singapore, Singapore

All Listed Sponsors
lead

National Cancer Centre, Singapore

OTHER